{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T01:17:48Z","timestamp":1778462268361,"version":"3.51.4"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,5,28]],"date-time":"2005-05-28T00:00:00Z","timestamp":1117238400000},"content-version":"vor","delay-in-days":6632,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Teratology"],"published-print":{"date-parts":[[1987,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The teratogenicity and developmental toxicity of valproic acid (VPA) was investigated in Sprague\u2010Dawley CD rats at doses of 0, 150, 200, 300, 400, and 600 mg\/kg administered by gavage on days 7\u201318 of gestation. The VPA\u2010600 dose was maternally toxic, causing death in two of four dams. This dose produced 100% embryonic resorption. The VPA\u2010400 dose was maternally toxic in as much as maternal weight gain was reduced, but no deaths occurred. At this dose five of fifteen litters were completely resorbed, and 52% of all embryos were resorbed. Among survivors, 49% were malformed (68% having skeletal defects and 41% visceral defects). Fetal weight was reduced by 43% in this group. Most of the defects were ectrodactyly, hydronephrosis, cardiovascular defects, hypoplastic bladder, rib and vertebral defects, and other defects of the limbs and tail. The VPA\u2010300 dose (nine litters) produced fewer defects, larger fetuses, and no increase in resorptions. The defects at this dose were primarily cariovascular, rib, and vertebral. The VPA\u2010200 dose (12 litters) produced no reduction in fetal weight, no increase in resorptions, and few defects. The defects noted were hydronephrosis, cardiovascular abnormalities, and rib defects, primarily wavy ribs. Additional litters were prepared using doses of 150 and 200 mg\/kg and were allowed to deliver and grow until 70 days. These doses produced no reduction in maternal weight gain, no reduction in litter size, birth weight, or sex ratio of the offspring. These doses produced no reduction in offspring weight to day 70, no increase in mortality, and only rare cases (two offspring of each dose) of tail defects. Maternal plasma VPA concentrations on day 18 of gestation showed values in excess of human therapeutic values (50\u2013130 \u03bcg\/ml) at 400 mg\/kg and values at or within the therapeutic range at 150 and 200 mg\/kg. The data support the view that VPA is mildly teratogenic in rats at human therapeutic plasma concentrations.<\/jats:p>","DOI":"10.1002\/tera.1420350205","type":"journal-article","created":{"date-parts":[[2005,6,11]],"date-time":"2005-06-11T15:01:36Z","timestamp":1118502096000},"page":"195-202","source":"Crossref","is-referenced-by-count":119,"title":["Teratogenicity and developmental toxicity of valproic acid in rats"],"prefix":"10.1002","volume":"35","author":[{"given":"Charles V.","family":"Vorhees","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,5,28]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)90018-6"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(80)91159-9"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320190308"},{"key":"e_1_2_1_5_1","first-page":"191","article-title":"Teratogenic effects of dosage levels and time of administration of carbamazepine, sodium valproate, and diphenylhydantoin on craniofacial development in the CD\u20101 mouse fetus","volume":"4","author":"Eluma F. O.","year":"1984","journal-title":"J. Cranio. Genet. Dev. Biol."},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)81210-4"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/tcm.1770010405"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90557-9"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(81)90541-5"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-0590(83)80067-0"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)90908-4"},{"key":"e_1_2_1_12_1","first-page":"249","volume-title":"Developmental Toxicology","author":"Vorhees C. V.","year":"1982"},{"key":"e_1_2_1_13_1","first-page":"106","volume-title":"Clinical and Pharmacological Aspects of Sodium Valproate (Epilim) in the Treatment of Epilepsy","author":"Whittle B. A.","year":"1975"},{"key":"e_1_2_1_14_1","first-page":"591","volume-title":"Antiepileptic Drugs","author":"Wilder B. J.","year":"1982"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1965.tb12260.x"}],"container-title":["Teratology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Ftera.1420350205","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/tera.1420350205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T06:46:49Z","timestamp":1695797209000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/tera.1420350205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1987,4]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1987,4]]}},"alternative-id":["10.1002\/tera.1420350205"],"URL":"https:\/\/doi.org\/10.1002\/tera.1420350205","archive":["Portico"],"relation":{},"ISSN":["0040-3709","1096-9926"],"issn-type":[{"value":"0040-3709","type":"print"},{"value":"1096-9926","type":"electronic"}],"subject":[],"published":{"date-parts":[[1987,4]]}}}